Intermediate Risk Prostate Cancer May Be Safely Controlled with Brachytherapy Alone

Intermediate Risk Prostate Cancer May Be Safely Controlled with Brachytherapy Alone
Patients with prostate cancer who receive brachytherapy alone have similar cancer control rates and fewer side effects compared to those who receive brachytherapy in combination with external beam therapy (EBT), according to the results of a Phase 3 clinical trial. The abstract, "Initial Report of NRG Oncology/RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma Identification and Validation of Intrinsic Subtypes of Prostate Cancer," was recently presented at the
Subscribe or to access all post and page content.